Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference

Rhea-AI Summary

Adverum Biotechnologies (NASDAQ: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced that its Chief Medical Officer, Richard Beckman, M.D., will participate in a fireside chat at the Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. The event will be accessible via an on-demand webcast, which will remain available for 90 days on the company’s website. Adverum aims to develop a one-time gene therapy, ixoberogene soroparvovec (Ixo-vec), to treat neovascular age-related macular degeneration, minimizing the need for frequent ocular injections.

REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Richard Beckman, M.D., chief medical officer of Adverum Biotechnologies, will participate in a fireside chat at Chardan’s 6^th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET.

The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for 90 days following the presentation.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Corporate & Investor Inquiries

Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com

Media

Megan Talon
Associate Director, Corporate Communications
Adverum Biotechnologies, Inc.
T: 650-649-1006
E: mtalon@adverum.com

FAQ

What is the purpose of Adverum's participation in the Chardan’s 6th Annual Genetic Medicines Conference?

Adverum Biotechnologies aims to discuss its gene therapy advancements and treatment strategies for ocular diseases.

When will Richard Beckman speak at the conference?

Richard Beckman will participate in the fireside chat on October 3, 2022, at 4:00 p.m. ET.

How can I access the webcast of Adverum's presentation?

The on-demand webcast can be accessed in the Events and Presentations section of Adverum’s website.

What is ixoberogene soroparvovec and what condition does it target?

Ixoberogene soroparvovec (Ixo-vec) is a gene therapy candidate being developed by Adverum to treat neovascular or wet age-related macular degeneration.

How long will the webcast replay be available after the conference?

The replay of the webcast will be available for 90 days following the presentation.